Lofepramine

Authors:

Abstract
Lofepramine is a tricyclic antidepressant that is structurally similar to imipramine and is extensively metabolised to desipramine. In the absence of other major pharmacological effects it appears that its antidepressant activity stems from the facilitation of noradrenergic neurotransmission by uptake inhibition, and possibly by the additional facilitation of serotoninergic neurotransmission. The overall therapeutic efficacy of lofepramine is comparable to that of imipramine, amitriptyline, clomipramine, maprotiline and mianserin in patients with depression of varying severity, and coexisting anxiety. Dry mouth is the most commonly reported side effect of usual therapeutic doses of lofepramine, but the incidence of this and other anticholinergic side effects is less among patients treated with lofepramine than with imipramine. Lofepramine has not been associated with adverse effects on cardiac function even in cases of attempted suicide by overdose. Thus, providing its apparent favourable side effect profile is confirmed in practice, lofepramine may be a valuable alternative for treatment of the depressed patient where a tricyclic is indicated. Lofepramine facilitates noradrenergic neurotransmission through potent inhibition of neuronal uptake of noradrenaline (norepinephrine). Various studies have shown that this effect occurs both in vitro and in vivo and lofepramine may also potentiate serotoninergic neurotransmission by inhibition of the neuronal uptake of serotonin and the enzyme tryptophan pyrrolase. Neurotransmitter receptor binding studies have shown that neither lofepramine nor its active metabolite desipramine antagonise α1-, α2 - or β1-adrenoceptors, although lofepramine did show some affinity for dopamine D1 and D2 receptors. In comparison with other tricyclic antidepressants lofepramine had a lower affinity for human muscarinic receptors in vitro. Lofepramine does not exhibit significant sedative effects in animal models and administration of single oral doses of lofepramine 70, 105 and 140mg had no adverse effects on reaction times in healthy subjects. In contrast with equimolar concentrations of amitriptyline, desipramine, imipramine, maprotiline, mianserin, nomifensine and zimeldine, intravenous infusion of lofepramine 0.5 mg/kg/min did not produce significant prolongations of electrocardiographic PQ and QRS times in anaesthetised rats. Single oral doses of lofepramine 70 to 140mg did not produce clinically significant cardiovascular effects in healthy subjects, unlike amitriptyline 50mg, which produced a statistically significant reduction in standing diastolic blood pressure (p < 0.05 vs lofepramine). Administration of single oral doses of lofepramine 140 and 210mg to healthy subjects demonstrated that lofepramine has little peripheral anticholinergic activity in comparison to amitriptyline 50 and 150mg, imipramine 150mg, maprotiline 150mg and mianserin 60mg. Following oral administration to healthy subjects lofepramine is rapidly absorbed and peak plasma concentrations of lofepramine and desipramine are achieved within 1 hour and 4 hours, respectively. However, lofepramine is subject to extensive first-pass metabolism to desipramine, by a hepatic microsomal cytochrome P450-dependent enzyme system; thus, the apparent bioavailability of oral lofepramine is below 10%. The plasma elimination half-life of lofepramine is rather short but the long elimination half-life of desipramine (12 to 24 hours) may lead to accumulation with repeated administration. Lofepramine is an effective antidepressant that has an onset of action of less than 2 weeks when administered in doses up to 210 mg/day to patients with various types of depression. Double-blind controlled studies have demonstrated that the overall antidepressant efficacy of lofepramine is significantly greater than placebo and comparable to that of imipramine, amitriptyline, clomipramine, maprotiline and mianserin. In three 6-week studies in depressed patients lofepramine produced reductions in Hamilton Rating Scale scores of about 60%, which were similar to those produced by imipramine and amitriptyline and greater than that produced by clomipramine. Furthermore, the results of two 4-week multicentre, non-comparative studies have indicated that lofepramine has significant anxiolytic efficacy in addition to its antidepressant properties. The most commonly reported side effects of lofepramine among 660 patients evaluated for tolerability in non-comparative and double-blind controlled studies were: dry mouth (17.6%), constipation (7.7%), dizziness (5.3%), sweating (5.2%), nausea and vomiting (4.7%), and tremor (3.3%). Overall, approximately 42.9% of patients who received lofepramine reported side effects of varying degrees of severity, but only 7.4% were actually withdrawn from treatment because of adverse effects, the results of comparative studies indicate that lofepramine treatment produces a lower incidence of adverse effects (particularly anticholinergic effects) than treatment with imipramine or amitriptyline. However, further large scale comparative studies are needed in order to assess the tolerability of lofepramine in relation to second generation antidepressants such as mianserin or trazodone. The usual dosage of lofepramine is 70mg 2 or 3 times a day, titrated according to the severity of the depressive illness.

This publication has 33 references indexed in Scilit: